FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. (FENC) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 89% planned / 11% discretionary
Largest single sale: $883.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Raykov Rosty | Other | Sell 10b5-1 | 10,000 | $12.11 | $121.1K | 124,411 −7.4% of holding | |
| Sayad Pierre Sargis | Chief Medical Officer | Sell | 12,000 | $12.18 | $146.2K | 9,519 −55.8% of holding | |
| Andrade Robert | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 75,000 | $11.78 | $883.5K | 217,675 −25.6% of holding | |
| Raykov Rosty | Other | Sell 10b5-1 | 10,000 | $9.58 | $95.8K | 131,633 −7.1% of holding | |
| Raykov Rosty | Other | Sell 10b5-1 | 9,599 | $10.41 | $99.9K | 138,855 −6.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.